Literature DB >> 22886769

Distinct tumor protein p53 mutants in breast cancer subgroups.

Anne Dumay1, Jean-Paul Feugeas, Evelyne Wittmer, Jacqueline Lehmann-Che, Philippe Bertheau, Marc Espié, Louis-François Plassa, Paul Cottu, Michel Marty, Fabrice André, Christos Sotiriou, Lajos Pusztai, Hugues de Thé.   

Abstract

Tumor protein p53 (TP53) is mutated in approximately 30% of breast cancers, but this frequency fluctuates widely between subclasses. We investigated the p53 mutation status in 572 breast tumors, classified into luminal, basal and molecular apocrine subgroups. As expected, the lowest mutation frequency was observed in luminal (26%), and the highest in basal (88%) tumors. Luminal tumors showed significantly higher frequency of substitutions (82 vs. 65%), notably A/T to G/C transitions (31 vs. 15%), whereas molecular apocrine and basal tumors presented much higher frequencies of complex mutations (deletions/insertions) (36 and 33%, respectively, vs. 18%). Accordingly, missense mutations were significantly more frequent in luminal tumors (75 vs. 54%), whereas basal tumors displayed significantly increased rates of TP53 truncations (43 vs. 25%), resulting in loss of function and/or expression. Interestingly, as basal tumors, molecular apocrine tumors presented with a high rate of complex mutations, but paradoxically, these were not associated with increased frequency of p53 truncation. As in luminal tumors, this could reflect a selective pressure for p53 gain of function, possibly through P63/P73 inactivation. Collectively, these observations point not only to different mechanisms of TP53 alterations, but also to different functional consequences in the different breast cancer subtypes.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22886769     DOI: 10.1002/ijc.27767

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases.

Authors:  Farah Jouali; Fatima Zahra El Ansari; Nabila Marchoudi; Amina Barakat; Hassaniya Zmaimita; Hamza Samlali; Jamal Fekkak
Journal:  Int J Mol Epidemiol Genet       Date:  2020-06-15

Review 2.  The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation.

Authors:  Arnold J Levine; Anna M Puzio-Kuter; Chang S Chan; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

3.  Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population.

Authors:  Emel Ebru Pala; Umit Bayol; Elif Usturali Keskin; Alp Ozguzer; Ulku Kucuk; Ozge Ozer; Altug Koc
Journal:  Pathol Oncol Res       Date:  2015-06-10       Impact factor: 3.201

4.  Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status.

Authors:  Rupninder Sandhu; Jessica Rein; Monica D'Arcy; Jason I Herschkowitz; Katherine A Hoadley; Melissa A Troester
Journal:  Carcinogenesis       Date:  2014-08-14       Impact factor: 4.944

Review 5.  Metabolism and immunity in breast cancer.

Authors:  Deyu Zhang; Xiaojie Xu; Qinong Ye
Journal:  Front Med       Date:  2020-10-19       Impact factor: 4.592

Review 6.  Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.

Authors:  Aaron M Udager; Simion I Chiosea
Journal:  Head Neck Pathol       Date:  2017-03-20

7.  p53 and ΔNp63α Coregulate the Transcriptional and Cellular Response to TGFβ and BMP Signals.

Authors:  Amanda L Balboni; Pratima Cherukuri; Matthew Ung; Andrew J DeCastro; Chao Cheng; James DiRenzo
Journal:  Mol Cancer Res       Date:  2015-02-19       Impact factor: 5.852

8.  SRC Increases MYC mRNA Expression in Estrogen Receptor-Positive Breast Cancer via mRNA Stabilization and Inhibition of p53 Function.

Authors:  Christopher Abdullah; Hasan Korkaya; Shinji Iizuka; Sara A Courtneidge
Journal:  Mol Cell Biol       Date:  2018-02-27       Impact factor: 4.272

9.  Adiposity is associated with p53 gene mutations in breast cancer.

Authors:  Heather M Ochs-Balcom; Catalin Marian; Jing Nie; Theodore M Brasky; David S Goerlitz; Maurizio Trevisan; Stephen B Edge; Janet Winston; Deborah L Berry; Bhaskar V Kallakury; Jo L Freudenheim; Peter G Shields
Journal:  Breast Cancer Res Treat       Date:  2015-09-12       Impact factor: 4.872

10.  Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.

Authors:  Xian Chen; Kwang-Huei Low; Angela Alexander; Yufeng Jiang; Cansu Karakas; Kenneth R Hess; Jason P W Carey; Tuyen N Bui; Smruthi Vijayaraghavan; Kurt W Evans; Min Yi; D Christian Ellis; Kwok-Leung Cheung; Ian O Ellis; Siqing Fu; Funda Meric-Bernstam; Kelly K Hunt; Khandan Keyomarsi
Journal:  Clin Cancer Res       Date:  2018-09-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.